iRadimed (NASDAQ:IRMD) Stock Rating Lowered by Wall Street Zen

iRadimed (NASDAQ:IRMD) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings downgraded shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, iRadimed has a consensus rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Stock Performance

NASDAQ IRMD opened at $92.50 on Friday. The stock’s 50-day moving average price is $94.55 and its two-hundred day moving average price is $95.35. The company has a market cap of $1.18 billion, a PE ratio of 51.68 and a beta of 0.90. iRadimed has a 1 year low of $67.84 and a 1 year high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Research analysts forecast that iRadimed will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the transaction, the chief executive officer owned 2,175,000 shares in the company, valued at $190,334,250. This represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 14,411 shares of company stock valued at $1,253,921. 34.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in iRadimed in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC grew its holdings in shares of iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares during the last quarter. CWM LLC raised its holdings in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in shares of iRadimed during the second quarter worth $84,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.